logo
Plus   Neg
Share
Email

Nektar Publishes Two Manuscripts On Its Immuno-oncology Candidate, Bempeg

Nektar Therapeutics (NKTR), a biopharmaceutical company, published preclinical data on its lead immuno-oncology candidate, NKTR-214, bempegaldesleukin (bempeg), an investigational CD122-preferential interleukin-2 pathway agonist designed to provide activation and proliferation of cancer-killing immune cells. The company said the data showed that bempeg, in combination with immune-based therapies including checkpoint inhibition, antigen-specific vaccination and adoptive cell transfer therapy, enhanced T-cell mediated tumor control.

Bempeg in combination with checkpoint inhibitors and other immune-mediating agents is being evaluated in clinical trials, Nektar Therapeutics noted.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. National Restaurant Association is launching a campaign to help restaurants reassure customers that they stick to healthy and safe standards, as the restaurant industry is struggling amid the coronavirus outbreak. The association and its food and beverage safety training and certificate program ServSafe announced the nationwide "ServSafe Dining Commitment". Luxury electric car maker Tesla Inc. (TSLA) announced Thursday that it delivered about 90,650 vehicles in the second quarter of 2020, while producing more than 82,000 vehicles. The deliveries include 80,050 Model 3 sedans and Model Y cross-over SUVs as well as 10,600 Model S and X vehicles. The... Boy Scouts of America recalled about 78,000 units of Cub Scout outdoor activity pins for violating the federal lead content ban, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the activity pin's face and shaft contain levels of lead that exceed the federal lead content ban. Lead is toxic if ingested by young children and can cause adverse health issues.
RELATED NEWS
Follow RTT